Skip to main content
Equibles
SLDB logo

SLDB · Solid Biosciences Inc.

Track SLDB — free

Use SLDB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLDB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.04 -0.02 (-0.28%)
Russell 2000 member Rebalance outlook locked
Market Cap
$781.67M
Shares
107.23M
Volume · Oct 5 1.37M Avg daily vol (3M) 1.13M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.06 Open$6.88 Day$6.77–7.21 52W close$3.93–11.15 Avg vol 30d1.2M Short int17.1M · 16.0% float · 19.6d Short vol75% Last earningsFeb 18, 2025 DataJan 2020–Oct 2026 Filing10-Q · Aug 6

Up next

Latest filing: 10-Q
filed Aug 6, 2026
Q1 2022 earnings call transcript
call held Apr 27, 2022

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+19.3%
Trailing year
Short interest
16.0%
Latest settlement · 19.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −7%
below
Price vs 50-day avg −19%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 43%
mid-range
Momentum
relative strength
Weak
1-month return −31%
trailing
6-month return −14%
trailing
YTD return +25%
this year
Relative strength −26%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow Flat
2 of 156 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.95% of float · ▲ +4.4% MoM · 19.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Weak
Revenue growth −41%
Y/Y
EPS growth +35%
Y/Y
Free cash flow $-157.4M
Quant / Vol
risk profile
Very High
Volatility 79%
annualized · 1-yr
Max drawdown −39%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−7% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow Flat
2 of 156 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.95% of float · ▲ +4.4% MoM · 19.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $7 · 43% Range high $11
vs 200-day avg -7% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLDB
Solid Biosciences Inc.
this stock
$781.67M +25.2% -40.6% — 16.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
156
% held
107.0%
Reported
2 of 156
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
159
View
Short & Settlement
Short Interest Rising
Shares short
17.1M
Days to cover
19.6d
Change
+722.1K sh
View
Short Volume
Short vol %
75%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
953
Value
$9.1K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
29.3%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$8.1M
Net income (FY)
$-117.2M
EPS diluted
$-1.99
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
9
View
Proposed Sales
Value
$32.4K
Shares
5.6K
Filed
Feb 18, 2026
View
Exempt Offerings
Offering
$9.2M
Filed
Dec 9, 2022
View
Earnings & Events
Webcasts
Last webcast
Feb 18, 2025
View

Performance

5D 20D 120D MTD YTD
SLDB -3.0% -31.1% -14.2% -2.4% +25.2%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -4.2% -31.7% -25.8% -4.0% +11.6%
Key facts CIK 1707502 CUSIP 83422E204 13F (30d) 4 filings 4 filers Visit website Investor relations